Notably, it includes insights into: (i) patients with IgA Vasculitis nephritis (excluded from the PROTECT trial) or proliferative IgA glomerulonephritis (such as necrotizing forms); (ii) patients with complex comorbidities and varying degrees of histologic chronicity/activity (including crescents and nephrotic-range proteinuria); and (iii) various combination therapy approaches, such as initial treatment with targeted-release budesonide, addition to ongoing mycophenolate therapy, and simultaneous use with SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and IgA glomerulonephritis.